Article ; Online: Nanoscale flow cytometry to distinguish subpopulations of prostate extracellular vesicles in patient plasma.
2019 Volume 79, Issue 6, Page(s) 592–603
Abstract: Objective: To determine if prostate-derived extracellular vesicles (EVs) present in patient plasma samples are of exocytotic origin (exosomes) or released by the cell membrane (microparticles/microvesicles). Both malignant and normal prostate cells ... ...
Abstract | Objective: To determine if prostate-derived extracellular vesicles (EVs) present in patient plasma samples are of exocytotic origin (exosomes) or released by the cell membrane (microparticles/microvesicles). Both malignant and normal prostate cells release two types of EVs into the circulation, exosomes, and microparticles/microvesicles which differ in size, origin, and mode of release. Determining what proportion of prostate-derived EVs are of exosomal versus microparticle/microvesicle EV subtype is of potential diagnostic significance. Materials and methods: Multi-parametric analytical platforms such as nanoscale flow cytometry (nFC) were used to analyze prostate derived extracellular vesicles. Plasmas from prostate cancer (PCa) patient plasmas representing benign prostatic hyperplasia (BPH), low grade prostate cancer (Gleason Score 3 + 3) and high grade prostate cancer (Gleason Score ≥4 + 4) were analyzed for various exosome markers (CD9, CD63, CD81) and a prostate specific tissue marker (prostate specific membrane antigen/PSMA). Results: By using nanoscale flow cytometry, we determine that prostate derived EVs are primarily of cell membrane origin, microparticles/microvesicles, and not all PSMA expressing EVs co-express exosomal markers such as CD9, CD63, and CD81. CD9 was the most abundant exosomal marker on prostate derived EVs (12-19%). There was no trend observed in terms of more PSMA + CD9 or PSMA + CD63 co-expressing EVs versus increasing grade of prostate cancer. Conclusion: The majority of prostate derived EVs present in plasmas are from the cell membrane as evidenced by their size and most importantly, lack of co-expression of exosomal markers such as CD9/CD63/CD81. In fact, CD81 was not present on any prostate derived EVs in patient plasmas whereas CD9 was present on a minority of prostate derived EVs. The addition of an exosomal marker for detection of prostate-derived EVs does not provide greater clarity in distinguishing EVs released by the prostate. |
---|---|
MeSH term(s) | Biomarkers/metabolism ; Cell-Derived Microparticles/metabolism ; Cell-Derived Microparticles/pathology ; Exosomes/metabolism ; Exosomes/pathology ; Extracellular Vesicles/classification ; Extracellular Vesicles/pathology ; Flow Cytometry/methods ; Humans ; Male ; Nanotechnology/methods ; Neoplasm Grading ; Prostate/metabolism ; Prostate/pathology ; Prostatic Hyperplasia/blood ; Prostatic Hyperplasia/pathology ; Prostatic Neoplasms/blood ; Prostatic Neoplasms/pathology ; Tetraspanin 29/analysis ; Tetraspanin 30/analysis |
Chemical Substances | Biomarkers ; Tetraspanin 29 ; Tetraspanin 30 |
Language | English |
Publishing date | 2019-01-24 |
Publishing country | United States |
Document type | Journal Article ; Research Support, Non-U.S. Gov't |
ZDB-ID | 604707-5 |
ISSN | 1097-0045 ; 0270-4137 |
ISSN (online) | 1097-0045 |
ISSN | 0270-4137 |
DOI | 10.1002/pros.23764 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 1608: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.